Bexsero (meningococcal group B vaccine) / GSK - LARVOL DELTA

Adult immunization. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Hepatitis B • Herpes Zoster • Infectious Disease • Inflammation • Influenza • Measles • Meningococcal Infections • Pertussis • Pneumococcal Infections • Respiratory Diseases • Respiratory Syncytial Virus Infections • Tetanus • Varicella Zoster

Comparison chart: Some vaccines for adults. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Hepatitis B • Infectious Disease • Inflammation • Influenza • Measles • Meningococcal Infections • Pertussis • Pneumococcal Infections • Respiratory Diseases • Respiratory Syncytial Virus Infections • Tetanus

A Multidesign Study of 4CMenB Vaccine Effectiveness and Impact on Meningococcal Carriage and Gonorrhea in Northern Territory Adolescents and Young People. (PubMed, Open Forum Infect Dis) - "These findings are important for women, considering infections are often asymptomatic and have the potential for serious complications. The NT has now introduced a 4CMenB infant and adolescent program."

Journal • Infectious Disease • Meningococcal Infections • Otorhinolaryngology

Defining the Efficacy of Meningococcal B Vaccines Against Gonococcal Acquisition: The Current Landscape. (PubMed, J Int AIDS Soc) - "Current evidence from RCTs does not support the use of 4CMenB to prevent gonorrhoea in gay and bisexual men at high risk of acquisition. Results from ongoing RCTs will be critical to determine whether vaccine efficacy varies by population or epidemiological context and to inform future gonorrhoea vaccine policy and development."

Journal • Review • Human Immunodeficiency Virus • Infectious Disease • Meningococcal Infections

Willingness to use meningococcal B vaccine (4CMenB) to prevent gonorrhoea among gay and bisexual men and non-binary people in Australia (AIDS 2026) - "Multivariable logistic regression examined factors associated with willingness to use the 4CMenB vaccine for gonorrhea prevention... Willingness to use a vaccine to prevent gonorrhoea was very high among GBM+, and was shaped more by engagement with sexual health services, biomedical prevention, and STI-related knowledge including antimicrobial resistance than by recent sexual behavior or gonorrhoea diagnosis. The high overall level of willingness suggests that integrating STI vaccinations into existing sexual health and PrEP pathways could facilitate rapid uptake among GBM+. Community-level education with clear messaging about a vaccine’s role in STI prevention will be critical for reaching GBM+ not yet engaged with prevention services."

Human Immunodeficiency Virus • Infectious Disease • Meningococcal Infections

GSK (GSK) announced the European Medicines Agency, EMA, has accepted a submission to update the label for Bexsero to include a single dose booster for individuals aged 10 years and older who were previously vaccinated with Bexsero. (TipRanks) - "The submission is supported by a Phase 3b, open-label, multi-centre study that evaluated the immune response of a Bexsero booster dose in individuals 10 to 20 years old who received the complete primary series during infancy."

European regulatory • Meningococcal Infections

SY24 How to address the rising STI epidemic (AIDS 2026) - "The session will aim to review the recent innovations in the field that might tackle the rising STI epidemic. The symposium will discuss real-world implementation of DoxyPEP, recent efficacy data from 4CMenB vaccine trials for gonorrhoea, usefulness of point-of-care testing and the different tools to respond to the resurgence of mpox."

Infectious Disease

What are we to do about rising gonorrhoea cases? The case for Bexsero vaccination (AIDS 2026) - No abstract available

Clinical • Infectious Disease

New era in STI prevention: early adoption of doxyPEP and 4CMenB vaccination among a community sample of men and gender-diverse people having sex with men in England-findings from a large, cross-sectional survey in 2025. (PubMed, Sex Transm Infect) - "Findings indicate substantial early adoption of doxyPEP and 4CMenB vaccination in England, with early 4CMenB vaccination appearing more uniform relative to doxyPEP. Ongoing monitoring is essential to identify emerging inequities and to understand factors driving them as rollout progresses."

Journal • Human Immunodeficiency Virus • Infectious Disease

Real-world effectiveness and impact of the 4CMenB vaccine against serogroup B invasive meningococcal disease: a systematic review and meta-analysis. (PubMed, NPJ Vaccines) - "This meta-analysis provides evidence of high 4CMenB VE against serogroup B-IMD in fully vaccinated infants and children across different geographic regions. Clinical trial registration: N/A."

Journal • Real-world evidence • Retrospective data • Infectious Disease • Meningococcal Infections

Discovery and characterization of an anti-Neisseria gonorrhoeae NGO_1985 monoclonal antibody and cognate antigen. (PubMed, Front Microbiol) - "Since partial protection against gonorrhea has reportedly been linked to vaccination with the anti-meningococcal 4CMenB vaccine, we utilized Reverse Vaccinology 2.0 to identify gonococcal antigens through characterization of monoclonal antibodies (mAbs) produced by memory B cells (MBCs) following vaccination of volunteers with 4CMenB...The NGO_1985 epitope recognized by mAb_4 was predicted in silico and experimentally confirmed by Hydrogen Deuterium Exchange Mass Spectrometry. This study enhances our understanding of the molecular basis for the cross-reaction/protection conferred by 4CMenB and might guide future developments of antibody cocktail therapeutics, protein-based vaccines, and in vivo research."

Journal • Infectious Disease • Meningococcal Infections

Bilateral abducens nerve palsy following Bexsero (meningococcal group B vaccine) administration - case report (EAN 2026) - No abstract available

Case report • Clinical • Infectious Disease • Meningococcal Infections

Metagenomic Analysis of the Pharynx in High Risk Partners (clinicaltrials.gov) - P=N/A | N=100 | Not yet recruiting | Sponsor: Guy's and St Thomas' NHS Foundation Trust

New trial • Infectious Disease

Efficacy of the 4CMenB vaccine against gonorrhoea among men who have sex with men in Hong Kong: a double-blind randomised placebo-controlled trial. (PubMed, Int J Infect Dis) - P3 | "The results did not show efficacy of the 4CMenB vaccine against gonorrhoea in MSM. Receipt of the vaccine may impact risk perception and behavioural practice thus affecting vaccinee's exposure risk to STIs."

Journal • Infectious Disease • Meningococcal Infections

Cost-Effectiveness of Routine Infant Meningococcal B Vaccination in the Netherlands. (PubMed, Infect Dis Ther) - "In the Netherlands, 4CMenB vaccination is likely to be cost-effective if MenB incidence increases by 24%. This comprehensive analysis provides decision-makers with new and updated information on the cost-effectiveness of infant vaccination with 4CMenB in the Netherlands."

HEOR • Journal • Infectious Disease • Meningococcal Infections

Vaccination Against Serogroup B Meningococcal Disease: Current Status and Future Perspectives-A Consensus Document of the World Association for Infectious Diseases and Immunological Disorders (WAidid). (PubMed, Vaccines (Basel)) - "4CMenB is an effective tool for preventing MenB IMD, although further studies are needed. Future strategies should prioritize age-targeted boosting and enhanced genomic surveillance to maximize impact."

Journal • Review • Immunology • Infectious Disease • Meningococcal Infections

Pre-clinical efficacy of a candidate outer membrane vesicle gonococcal vaccine in comparison with 4CMenB. (PubMed, NPJ Vaccines) - "Meningococcal vaccines MeNZB and 4CMenB (Bexsero), containing Neisseria meningitidis group B detergent-extracted outer membrane vesicles (dOMV), cross-protect against gonorrhoea with 31-59% effectiveness...nOMV derived from GC_0817560lpxL1-rmp- and FA1090lpxL1-rmp- induced greater quantities of gonococcal-specific serum IgG and accelerated clearance of FA1090 from oestradiol-treated BALB/c mice significantly faster than 4CMenB and NZ98/254lpxL1-rmp- nOMV (P < 0.0001). Gonococcal nOMV-based vaccines represent promising candidates for further development."

Journal • Preclinical • Infectious Disease • Meningococcal Infections • IL6

IMMUNOGENICITY OF 4CMENB VACCINE IN ADOLESCENTS/YOUNG ADULTS AGED 10–-25 YEARS: SYSTEMATIC REVIEW AND META-ANALYSIS (ESPID 2026) - "High seroprotection rates across all evaluated 2-dose schedules (pooled ≥1-, 1- and 2-month intervals) and reported data from 6-month interval support dosing flexibility. This may facilitate the design of vaccine programs with flexible schedules targeting unmet needs, thereby supporting high vaccination coverage."

Retrospective data • Review • Infectious Disease • Meningococcal Infections

IMMUNOGENICITY OF 4CMENB VACCINE IN INFANTS VACCINATED WITH 2+1 OR 3+1 SCHEDULES: A SYSTEMATIC REVIEW AND META-ANALYSIS (ESPID 2026) - "Conclusions/Learning Points 4CMenB vaccine provides robust immunogenicity in infants when vaccination is completed by 15 or 24 months of age using 2+1 or 3+1 schedules. Evidence of similar responses with later completion supports flexibility, facilitating the design of adaptable vaccine programs to target unmet public health needs."

Retrospective data • Review • Infectious Disease • Meningococcal Infections

EARLY DECLINE IN MENB DISEASE AMONG VACCINE-ELIGIBLE YOUNG CHILDREN AFTER RECENT VACCINE POLICY CHANGES IN FRANCE (ESPID 2026) - "Background In France, infant 4CMenB vaccination was recommended in 2022, and infant MenB and MenACWY vaccination became mandatory in January 2025...Conclusions/Learning Points Early post-policy changes in France are more evident in age-specific incidence than in clinical presentation. The strongest signal is an early decline in MenB disease among vaccine-eligible young children, consistent with an early cohort effect."

Clinical • Infectious Disease • Meningococcal Infections • Septic Shock

PAEDIATRIC INVASIVE MENINGOCOCCAL DISEASE IN PORTUGAL: 17 YEARS OF EPIDEMIOLOGICAL AND GENOMIC SURVEILLANCE FOLLOWING MENC AND 4CMENB VACCINE INTRODUCTION (ESPID 2026) - "Although previous studies indicate moderate to high 4CMenB coverage of MenB strains, the persistence of MenB disease indicates the emergence of new genetic variants that may have low coverage. These findings underscore the need for ongoing laboratory surveillance and genomic monitoring to guide vaccination strategies for children and adolescents."

Clinical • Infectious Disease • Meningococcal Infections

EVIDENCE OF 4CMENB-INDUCED GONOCOCCAL ANTIBODY IMMUNITY IN HUMANS (ESPID 2026) - "Together, these data provide a potential mechanistic explanation of cross-protection observed in the clinic. Funding: GSK."

Infectious Disease • Meningococcal Infections

A NARRATIVE REVIEW OF EVIDENCE ON VACCINE EFFECTIVENESS AGAINST GONORRHOEA BY THE MENINGOCOCCAL 4CMENB VACCINE: A PUBLIC HEALTH VALUE PERSPECTIVE (ESPID 2026) - "This narrative review highlights the need for future research examining VE of 4CMenB against gonorrhoea in the general population, stratified by prior exposure status, to assess its importance in the VE causal pathway and to ascertain where 4CMenB can be best placed in National Immunisation Programmes for maximum benefit to patients and healthcare systems. Funding: GSK."

Review • Infectious Disease • Meningococcal Infections

Meningococcal B Vaccine in Patients with Asplenia (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: Medical University of Vienna | Active, not recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Meningococcal Infections

Efficacy of the serogroup B Neisseria meningitidis vaccine (4CMenB) in preventing experimental Neisseria gonorrhoeae urethral infection: a double-blind randomised controlled human challenge study protocol. (PubMed, BMJ Open) - P2 | "This is a double-blind randomised controlled trial testing the efficacy of the FDA-approved 4CMenB vaccine in preventing experimental N. gonorrhoeae infection...Data collection for this study is ongoing. NCT05294588."

Clinical protocol • Journal • Infectious Disease • Meningococcal Infections • Vaginitis